Zhang Li, Yuan Shi-Zhen
Second Affiliated Hospital, Nanhua University, Hengyang 421001, China.
Hepatobiliary Pancreat Dis Int. 2002 Nov;1(4):620-3.
To detect the relations of c-erbB-2 oncogene protein, epidermal growth factor receptor (EGFR) and transforming growth factor-beta1 (TGF-beta1) to the progression or metastasis of pancreatic carcinoma.
Using streptavidinbiotin complex (SABC) method, c-erbB-2 oncongene protein, we examined immunohistochemically EGFR and TGF-beta1 expressions in wax-tissue sections from 10 individuals with normal pancreas (NP), 13 patients with chronic pancreatitis (CP) and 36 patients with pancreatic ductal adenocarcinoma (PC).
The positive expression rates of c-cerbB-2 oncogene protein, EGFR and TGF-beta1 in the NP, CP and PC groups were 0, 0, 10%; 7.7%, 7.7%, 7.7%; and 41.7%, 50.0%, 44.4%, respectively. The positive expression rates of the three specific proteins increased more significantly in the PC group than in the NP and CP groups (P<0.05). The individual expression of c-erbB-2, EGFR and TGF-beta1 was not related to the age and sex of the patients as well as the site, size and histopathological grade of tumors (P>0.05), but to the clinical stage of tumors (P<0.01). The coexpression rate of the three proteins was 27.8% (10/36). This coexpression in the PC group was correlated with the histopathological grades and clinical stages of tumors (P<0.01).
Detection of c-erbB-2 oncogene protein, EGFR, and TGF-beta1 expressions in pancreatic tissue is helpful to judge the malignancy, progression, and metastasis of PC.
检测c-erbB-2癌基因蛋白、表皮生长因子受体（EGFR）和转化生长因子-β1（TGF-β1）与胰腺癌进展或转移的关系。
采用链霉亲和素-生物素复合物（SABC）法，免疫组织化学检测10例正常胰腺（NP）、13例慢性胰腺炎（CP）患者及36例胰腺导管腺癌（PC）患者石蜡组织切片中c-erbB-2癌基因蛋白、EGFR和TGF-β1的表达。
NP组、CP组和PC组中c-cerbB-2癌基因蛋白、EGFR和TGF-β1的阳性表达率分别为0、0、10%；7.7%、7.7%、7.7%；41.7%、50.0%、44.4%。PC组中这三种特异性蛋白的阳性表达率比NP组和CP组显著升高（P<0.05）。c-erbB-2、EGFR和TGF-β1的个体表达与患者的年龄、性别以及肿瘤的部位、大小和组织病理学分级无关（P>0.05），但与肿瘤的临床分期有关（P<0.01）。三种蛋白的共表达率为27.8%（10/36）。PC组中的这种共表达与肿瘤的组织病理学分级和临床分期相关（P<0.01）。
检测胰腺组织中c-erbB-2癌基因蛋白、EGFR和TGF-β1的表达有助于判断PC的恶性程度、进展和转移情况。
